Home › Lymphoma › Pennsylvania › Philadelphia
Lymphoma clinical trials in Philadelphia, PA
15 studies for Lymphoma are looking for participants at sites in and around Philadelphia (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
RecruitingPhase 1
- University of Pennsylvania - Abramson Cancer Center, Philadelphia
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
RecruitingPhase 2
- University of Pennsylvania, Philadelphia
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
RecruitingPhase 1
- The Children's Hospital of Philadelphia (CHOP), Philadelphia
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
RecruitingPhase 1/2
- Children's Hospital of Philadelphia-Center for Childhood Cancer Research, Philadelphia
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
RecruitingPhase 1/2
- Research Site, Philadelphia
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
RecruitingPhase 1/2
- Children's Hospital of Philadelphia, Philadelphia
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
RecruitingPhase 1
- Thomas Jefferson University, Philadelphia
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RecruitingPhase 1
- Hospital of the University of Pennsylvania, Philadelphia
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
RecruitingPhase 1/2
- Thomas Jefferson University, Philadelphia
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RecruitingPhase 1/2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
RecruitingPhase 1
- Children's Hospital of Philadelphia, Philadelphia
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RecruitingPhase 1
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RecruitingObservational study
- Children's Hospital of Philadelphia, Philadelphia
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
RecruitingObservational study
- Saint Christopher's Hospital for Children, Philadelphia
CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
RecruitingPhase 1
- University of Pennsylvania - Abramson Caner Center, Philadelphia
About Lymphoma
Lymphoma is a cancer affecting the immune system. Hodgkins Lymphoma and Non Hodgkins Lymphoma are types of lymphoma. Learn about symptoms and treatments.
More about Lymphoma on MedlinePlus
Lymphoma trials in other cities
- Houston, TX34 studies
- Boston, MA33 studies
- New York City, NY33 studies
- Washington, DC23 studies
- Baldwin Park, CA21 studies
- Chicago, IL20 studies
- Durham, NC17 studies
- St. Louis, MO15 studies
- Cleveland, OH13 studies
- Edison, NJ12 studies
- Seattle, WA12 studies
- Atlanta, GA11 studies
Other studies in Philadelphia
- Cancer (all types)60 studies
- Breast Cancer56 studies
- Non-Small Cell Lung Cancer51 studies
- Metastatic Cancer46 studies
- Colorectal Cancer44 studies
- Ovarian Cancer44 studies
- Prostate Cancer44 studies
- Lung Cancer36 studies
- Acute Myeloid Leukemia34 studies
- Heart Failure31 studies
- Endometrial Cancer29 studies
- Head and Neck Squamous Cell Carcinoma26 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.